Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : GlaxoSmithKline Biologicals
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 4 ans
A phase III, open, randomized, trial to evaluate the immunogenicity and safety of a single or two-dose schedule of the A/California/7/2009 (H1N1)v-like candidate vaccine manufactured in Dresden adjuvanted with AS03A, in adults aged 18 years and above
To demonstrate that vaccination with one dose of the H1N1 candidate vaccine (A/California/7/2009 (H1N1)v-like strain) containing 3.75 µg of HA adjuvanted with AS03A results in an Haemagglutination Inh...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 4 ans
Immunogenicity and safety study of GSK Biologicals’ meningococcal vaccine GSK 134612 administered to at risk subjects from 1 to less than 18 years. Hodnocení imunogenity a bezpečnosti meningokokové vakcíny GSK134612 společnosti GSK Biologicals u rizikových subjektů od 1 do 18 let
To evaluate the immunogenicity of 1 and 2 doses of GSK 134612 administered to at risk subjects compared to age-matched healthy subjects in terms of vaccine response rates to meningococcal antigens.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 4 ans
A phase III, observer-blind, multicountry, multicentre study to evaluate the safety, reactogenicity and immunogenicity of GlaxoSmithKline Biologicals’ GSK2186877A influenza vaccine administered to adults aged 65 years and older compared to Fluarix™ administered to adults aged 18-41 years and 65 years and older, who previously participated in the 110847 study
To assess the safety and reactogenicity during the entire study period in subjects aged 65 years or older (previously enrolled in the 110847 study) vaccinated with the FLU NG vaccine or with Fluarix, ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 4 ans
A phase III, double-blind, randomized, controlled study to evaluate the safety, immunogenicity and efficacy of GlaxoSmithKline Biologicals’ HPV 16/18 L1/AS04 vaccine administered intramuscularly according to a three-dose schedule (0, 1, 6 month) in healthy adult female subjects aged 26 years and above
To demonstrate efficacy of the candidate vaccine in the prevention of (1) persistent infection (6-month definition) with HPV-16 or HPV-18 (by polymerase chain reaction [PCR]) and/or (2) histopathologi...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 4 ans
A Phase III, open, non-randomized, multi-centric, single dose study to assess immunogenicity and safety of Fluarix™ (Influsplit SSW®) 2007/2008 injected intramuscularly in young adults (18 to 60 years) and in elderly (over 60 years)
To evaluate the humoral response (anti-hemagglutinin antibody tested by hemagglutination inhibition) against each vaccine strain in adults aged 18 years or above 21 days after vaccination with Fluarix...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 4 ans
A randomized, double-blind, placebo-controlled, post-marketing phase III Study to evaluate the efficacy of GSK Biologicals’ influenza vaccine (Fluarix™) administered intramuscularly in adults
To demonstrate the efficacy of Fluarix compared with placebo (normal saline solution) in the prevention of culture confirmed influenza A and /or B in adults.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 4 ans
Study to evaluate the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ inactivated polio vaccine (Poliorix) in infants
To demonstrate the non-inferiority of GSK Biologicals’ IPV vaccine as compared to the Chinese OPV vaccine in terms of the immune response to poliovirus type 1, 2 and 3, one month after the third vacci...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 4 ans
Immunogenicity and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ DTPa-HBV-IPV/Hib vaccine’s new formulation as com-pared with DTPa-HBV-IPV/Hib vaccine’s current formulation when administered in healthy infants at 3, 4 and 5 months of age
To demonstrate that the immunogenicity of the DTPa-HBV-IPV/Hib vaccine (new formulation) in terms of response to all vaccine antigens is non-inferior to that of the DTPa-HBV-IPV/Hib vaccine (current f...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 4 ans
A phase III, double-blind, randomized study to demonstrate the non-inferiority of an aged lot of GlaxoSmithKline Biologicals' FLU NG vaccine in adults aged 65 years and above compared to a fresh lot of GlaxoSmithKline Biologicals' FLU NG vaccine
To assess the immunological non-inferiority (in terms of Haemagluttination Inhibition (HI) antibody Geometric Mean Titers (GMT)) of an aged lot of the FLU NG vaccine 21 days after vaccination in elder...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
GlaxoSmithKline Biologicals
MAJ Il y a 4 ans
Immunogenicity and safety study of GlaxoSmithKline Biologicals' HPV vaccine (GSK-580299) and Merck's Gardasil® vaccine when administered according to alternative 2-dose schedules in 9-14 years old females
- To evaluate sequentially if the immunogenicity (as determined by ELISA) of GSK Biologicals’ HPV-16/18 L1 VLP AS04 vaccine administered according to a 2-dose schedule at 0, 6 months is non-inferior/s...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
17
18
19
20
21
22
23
24
25
26
Suivant